Forest Laboratories To Acquire Aptalis For $2.9 Billion In Cash | Latest News RSS feed

Forest Laboratories To Acquire Aptalis For $2.9 Billion In Cash - Latest News


Aptalis to be Acquired by Forest Laboratories for $2.9 Billion

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Aptalis, a privately-held leading specialty pharmaceutical company, today announced that it has signed a definitive agreement to be acquired by Forest Laboratories ... read more

Forest Labs (FRX) to Acquire Privately-Held Aptalis in $2.9B Deal

Forest Laboratories, Inc. (NYSE: FRX) announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal (GI) and Cystic Fibrosis comp... read more

Forest Laboratories - Aptalis Deal Sparks More Enthusiasm

Acquisition Of Aptalis Forest Laboratories announced that it will acquire Aptalis for $2.9 billion in cash. Forest will acquire the privately held company from private investment firm TPG, among other... read more

Looking for another news?


Forest Labs buying Aptalis for $2.9 billion

NEW YORK (AP) -- Forest Laboratories is buying Aptalis, which specializes in treatments for gastrointestinal problems and cystic fibrosis, for $2.9 billion in cash. Shares of Forest Labs surged in pre... read more


Forest Labs To Acquire Furiex Pharma A Deal Potentially Worth $1.46 Billion

This afternoon, Forest ... 2.9 billion acquisition of Aptalis earlier this year,” said Brent Saunders, Chief Executive Officer and President of Forest Laboratories, Inc. Furiex is a drug development c... read more

Forest Labs to Buy Furiex Pharmaceuticals

The wave of deal-making in the drug industry continued on Monday when Forest Laboratories agreed to acquire Furiex Pharmaceuticals for up ... of our G.I. business following our $2.9 billion acquisitio... read more

Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development

Forest Laboratories (NYSE: FRX ... In January 2014, Forest acquired Aptalis Pharmaceuticals for $2.9 billion in cash in order to gain access to its GI and Cystic Fibrosis products, including treatment... read more

Forest Labs Soars on Aptalis Deal

Forest Laboratories, Inc. (NYSE:FRX) announced its intention to acquire U.S. based privately-held Aptalis for $2.9 billion in cash. The acquisition, which is expected to be immediately accretive, is s... read more

Actavis to buy Forest Labs in $25 billion deal (Update 3)

The Commack, N.Y., branch of Forest Laboratories, a Manhattan-based pharmaceutical company, is seen in this Aug. 4, 2004, file photo. Actavis PLC plans to buy Forest Laboratories Inc. in an approximat... read more

Actavis to buy Forest Labs in $25 billion deal

Actavis PLC plans to buy Forest Laboratories Inc. for about $25 billion ... Forest CEO Brent Saunders, who took over last fall, a few weeks ago completed a $2.9 billion purchase of Aptalis, which make... read more

Forest Labs to Buy Specialty Drug Maker for $2.9 Billion

Forest Laboratories said on Wednesday that it had agreed to buy Aptalis, a privately held drug maker, for $2.9 billion in cash. Aptalis, based in Bridgewater, N.J., produces treatments for cystic fibr... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us